Company news
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news
Aclaris Therapeutics, Inc. news releases on 6ix. Latest, Jun 8, 2021: Aclaris Announces Proposed Public Offering of Common Stock
Press releases — page 3
Aclaris Announces Proposed Public Offering of Common Stock
June 7, 2021
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 16, 2021
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 6, 2021
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
March 14, 2021
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
February 24, 2021
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 9, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
January 18, 2021
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 15, 2020
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
November 3, 2020
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
October 19, 2020
Aclaris Therapeutics to Present at Upcoming Investor Conferences
August 31, 2020
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
August 6, 2020
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
July 6, 2020
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
June 16, 2020
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
June 2, 2020
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 25, 2020
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
May 6, 2020
Aclaris Therapeutics Secures $11 Million Term Loan Facility
March 30, 2020
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
February 24, 2020
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
February 18, 2020
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 9, 2020
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
January 8, 2020
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
January 7, 2020
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
November 6, 2019
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
October 30, 2019
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
October 23, 2019
Aclaris Therapeutics Announces Divestiture of RHOFADE®
October 9, 2019
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
October 7, 2019
Aclaris Therapeutics to Hold R&D Day
September 16, 2019
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
September 15, 2019